FXR/TGR5 activation not only is a clear and highly safe target but also effectively regulates glucose and lipid metabolism, modulates the inflammatory response, and regulates immune homeostasis to delay the progression of DKD. Here, GPBAR1 is linked to diabetic kidney disease.